Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Core Viewpoint - Immutep Limited has reached 50% of its patient enrollment target in the TACTI-004 Phase III trial for eftilagimod alfa (efti) in combination with KEYTRUDA and chemotherapy for advanced/metastatic non-small cell lung cancer [1][7]. Group 1: Trial Progress and Details - The TACTI-004 trial has enrolled 378 patients globally, with enrollment continuing at a robust pace [3][7]. - The trial is set to complete patient enrollment by the third quarter of 2026, with a futility analysis expected in the first quarter of the same year [2][3]. - The study aims to enroll approximately 756 patients across over 150 clinical sites in more than 25 countries, regardless of PD-L1 expression [4]. Group 2: Efti and Its Mechanism - Efti is a first-in-class MHC Class II agonist that activates antigen-presenting cells to initiate a broad anti-cancer immune response [5]. - The immunotherapy is being evaluated for various solid tumors, including non-small cell lung cancer, and has received Fast Track designation from the FDA for first-line treatments [6]. Group 3: Company Overview - Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases, leveraging its expertise in LAG-3 therapeutics [8].